Floatz logo

LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine

Nonneoplastic Condition

Cancer Research UKPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Nonneoplastic Condition cohort.

Asset / SponsorPhaseRating
Inno-206
SWOG Cancer Research Network
Phase 2B
PREDNISONE TABLETS
SWOG Cancer Research Network
Phase 2B
FILGRASTIM
SWOG Cancer Research Network
Phase 2B
Procarbazine
SWOG Cancer Research Network
Phase 2B
Quadrivalent Human Papillomavirus Recombinant Vaccine
AIDS Malignancy Consortium
Phase 2B

View all 15 →

Same molecule, other indications

LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine is also rated in:

lymphoproliferative syndromeDormant
CC
Indicative ·
47 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →